|
Overview
Traditional non-steroidal anti-inflammatory
drugs (NSAIDs) are generally well-tolerated but they do cause
adverse GI effects in some patients. Because these agents
are so widely used, the aggregate morbidity and mortality
resulting from their adverse effects is significant.
Cyclooxygenase-2 (COX-2) inhibitors constitute
a new group of NSAIDs which block prostaglandin production
by cyclooxygenase-2, but not by cyclooxygenase-1. (Traditional
NSAIDs block both.) Clinical trials have shown that COX-2
inhibitors are equivalent in efficacy to nonselective NSAIDs
and have a lower incidence of GI toxicity.
In this interactive course we will review the
clinical pharmacology of COX-2 inhibitors and discuss the
role of COX-2 inhibitors in pain management and in neurodegenerative
disease.
Learning Objectives
Upon completion of this course,
you should be able to:
Target Audience
This CE activity is designed
designed for nurse practitioners as well as other healthcare
providers who are involved in the diagnosis and treatment
of patients with chronic pain.
Learner Participation to Earn Credit
Faculty Disclosures
Suzanne Holm, MS, ARNP, CS [BioSketch]
Adult Primary Care Nurse Practitioner
and Clinical Preceptor, Department of Family Medicine, University
of South Florida, Tampa, Florida
Disclosure: No financial relationships with a commercial
party to disclose.
|
